Antiperlecan Antibodies Are Novel Accelerators of Immune-Mediated Vascular Injury

作者：Cardinal H; Dieude M; Brassard N; Qi S; Patey N; Soulez M; Beillevaire D; Echeverry F; Daniel C; Durocher Y; Madore F; Hebert M J^*

来源：American Journal of Transplantation, 2013, 13(4): 861-874.

DOI：10.1111/ajt.12168

• Acute rejection
• antibodies
• apoptosis
• kidney transplantation

Acute vascular rejection (AVR) is characterized by immune-mediated vascular injury and heightened endothelial cell (EC) apoptosis. We reported previously that apoptotic ECs release a bioactive C-terminal fragment of perlecan referred to as LG3. Here, we tested the possibility that LG3 behaves as a neoantigen, fuelling the production of anti-LG3 antibodies of potential importance in regulating allograft vascular injury. We performed a casecontrol study in which we compared anti-LG3 IgG titers in kidney transplant recipients with AVR (n= 15) versus those with acute tubulo-interstitial rejection (ATIR) (n= 15) or stable graft n= 30). Patients who experienced AVR had elevated anti-LG3 titers pre and posttransplantation compared to subjects with ATIR or stable graft p<0.05 for both mediators). Elevated pretransplant anti-LG3 titers (OR: 4.62, 95% CI: 1.0819.72) and pretransplant donor-specific antibodies (DSA) (OR 4.79, 95% CI: 1.0322.19) were both independently associated with AVR. To address the functional role of anti-LG3 antibodies in AVR, we turned to passive transfer of anti-LG3 antibodies in an animal model of vascular rejection based on orthotopic aortic transplantation between fully MHC-mismatched mice. Neointima formation, C4d deposition and allograft inflammation were significantly increased in recipients of an ischemic aortic allograft passively transferred with anti-LG3 antibodies. Collectively, these data identify anti-LG3 antibodies as novel accelerators of immune-mediated vascular injury and obliterative remodeling.

• 出版日期2013-4